Skip to main navigation
Skip to content
InMed-logo-01

    Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Capabilities
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
  • Pharmaceutical Programs

  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Cannabinoids in Development
  • Cannabinoid Products

  • Products
    • Cannabichromene (CBC)
    • Cannabicitran (CBT
    • Cannabidivarin (CBDV)
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • FAQ
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu

    Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Capabilities
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
  • Pharmaceutical Programs

  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Cannabinoids in Development
  • Cannabinoid Products

  • Products
    • Cannabichromene (CBC)
    • Cannabicitran (CBT
    • Cannabidivarin (CBDV)
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • FAQ
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Subscribe
NASDAQ_Logo

InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference

November 23, 2021
PDF Version

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on November 29 – December 1, 2021.

Cowen's 4th Annual Cannabis Conference

Date: November 29 - December 1, 2021

Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your Cowen institutional representative or visit the conference website at https://www.cowen.com/conferences-and-events/4th-annual-cannabis-conference/

Cowen’s 4th Annual Cannabis Conference is a three-day conference comprising of topical panel discussions with C-Suite presenters, hosted by Cowen Research and Washington Research Group analysts, and virtual one-on-one meetings.

About InMed: InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

Investor Contact:
Colin Clancy
Senior Director, Investor Relations
T: +1 604 416 0999
E: cclancy@inmedpharma.com

Edison Group:
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
E: jgreen@edisongroup.com / lyonker@edisongroup.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: participating in Cowen’s 4th Annual Cannabis Conference; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; and developing a pipeline of cannabinoid-based pharmaceutical drug candidates. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.


Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Rare Cannabinoid Manufacturing

Manufacturing

  • Cannabinoid Manufacturing Capabilities
  • IntegraSyn™ - Cannabinoid Manufacturing
  • Baymedica Cannabinoid Biosynthesis

Pharmaceutical Programs

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Cannabinoids in Development

IR Nav

Investor

  • News Releases
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

Products

  • Cannabichromene (CBC)
  • Cannabicitran (CBT)
  • Cannabidivarin (CBDV)

About

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • FAQ
  • Careers
  • Contact

Learn

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabis Treatments for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

Legal Nav

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer

Social icons

  • Find Us On:
  • >
  • >
  • >